ALTAVANT SCIENCES GMBH has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are SCANDION ONCOLOGY AS, SIDEM PHARMA and IVAX CR A S.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Alonso-Galicia Magdalena | 8 |
#2 | Pack Thomas | 8 |
#3 | Wring Steve | 4 |
#4 | Rurka Julie | 4 |
#5 | Rhodes Melissa | 4 |
#6 | Carpenter David | 4 |
#7 | Goldberg Daniel R | 2 |
#8 | Rajagopal Sudarshan | 2 |
#9 | Palacios Michelle | 2 |
#10 | De Lombaert Stephane | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020188352A1 | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing | |
WO2020157577A1 | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
WO2020128614A1 | Method for treating interstital lung disease | |
WO2020128608A1 | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension | |
WO2020099926A1 | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |